American Journal of Psychiatry

Article	Citations
Highlights From the Residents’ Journal: December 2021	553
Treating Pathologies of the Will	236
Integrating Clinical and Basic Research: Opioid Use Disorder, Psychotic Illnesses, and Prefrontal Microcircuits Relevant to Schizophrenia	178
Evaluating Associations Between Cannabis and Heroin Use	161
Broadening the Parameters of Clinical High Risk for Psychosis	143
2024 Annual Meeting: Presidential Address	135
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	132
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	132
Depression, Inflammation, and Postpartum Psychosis	124
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	112
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	112
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	108
Intentional Drug Overdose Deaths in the United States	104
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	99
Mental Health Disparities Research: An Introduction to New Directions	98
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	93
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	92
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	86
Genes To Mental Health (G2MH): A Framework to Map the Combined Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology	86
20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis	81
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	79
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	77
Cannabis and Brain Health: What Is Next for Developmental Cohort Studies?	76
Correcting Overestimations in Self-Harm Visit Data	74
Suicide and the Menstrual Cycle	69

Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	68
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	67
Correction to Poirot et al.	66
Corrigendum to Morley et al.	66
2024 Annual Meeting: CEO and Medical Director’s Address	65
New Insights Into Psychotic Disorders	63
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	63
Highlights From the Residents’ Journal: September 2024	62
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	60
Back to the Future: Esmethadone, the (Maybe) Nonopiate Opiate, and Depression	60
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	59
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	56
The First Large GWAS Meta-Analysis for Postpartum Depression	56
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	54
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	54
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	53
Familial Risk of Postpartum Psychosis	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	51
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial	51
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	51
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	49
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	48
Risk of Incident Psychosis and Mania With Prescription Amphetamines	48
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	48
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	48
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	47
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	46
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	46
Proof-of-Principle Study on ECT Illustrates Challenges and Possible Merits of Using Polygenic Risk Scores to Predict Treatment Response in Psychiatry	46
The Safety of Pimavanserin for Parkinson’s Disease and Efforts to Reduce Antipsychotics for People With Dementia	45
Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings	45
Ketamine for Depression, but at What Cost? A Review of Ketamine’s Neurotoxic Effects From Preclinical and Human Studies	44
Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”	44
Aberrant Developmental Patterns of Gamma-Band Response and Long-Range Communication Disruption in Youths With 22q11.2 Deletion Syndrome	42
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	42
Sexual Identity Continuity and Change in a U.S. National Probability Sample of Sexual Minority Adults: Associations With Mental Health and Problematic Substance Use	41
Alcohol and the Etiology of Depression	41
Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment	40
The Neglected Role of Psychotherapy for Treatment-Resistant Depression	40
Shared and Specific Neural Correlates of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Meta-Analysis of 243 Task-Based Functional MRI Studies	39
Predictive Value of Acute Neuroplastic Response to rTMS in Treatment Outcome in Depression: A Concurrent TMS-fMRI Trial	39
From Crisis to Action: Psychiatry’s Ethical Imperative to Defend Transgender People’s Rights, Dignity, and Access to Care	39
2021 Articles of Import and Impact	37
Reduction in Trauma-Related Symptoms After Anesthetic-Induced Intra-Operative Dreaming	37
Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD	37
Synaptic Variability and Cortical Gamma Oscillation Power in Schizophrenia	37
Suicide in Black Females	37
Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial	36
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders	36
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression	36

Neural Correlates of Stress and Alcohol Cue-Induced Alcohol Craving and of Future Heavy Drinking: Evidence of Sex Differences	36
Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder	35
Psilocybin: From Psychiatric Pariah to Perceived Panacea	35
Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain	35
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary	35
Can Smartphone-Based Support Apps Add Value to the Treatment of Opioid Use Disorder?	35
Predicting Acute Changes in Suicidal Ideation and Planning: A Longitudinal Study of Symptom Mediators and the Role of the Menstrual Cycle in Female Psychiatric Outpatients With Suicidality	35
What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis	35
Drug Cues Trigger Corticolimbic Hyperreactivity in Heroin Users	33
Correction to Baum et al.	33
Keeping Track and Providing Tools for Future Crisis Management: Suicide Attempt and Self-Harm Presentations at Emergency Departments	32
Interindividual Differences in Cortical Thickness and Their Genomic Underpinnings in Autism Spectrum Disorder	32
The Association of Childhood Maltreatment and Mental Health Problems: Partly Causal and Partly Due to Other Factors	32
Harnessing the Power of Population Cohorts to Study the Relationship Between Endocrine-Metabolic Disorders and Depression	32
Racial and Ethnic Biases and Psychiatric Misdiagnoses: Toward More Equitable Diagnosis and Treatment	32
Beneath the Phenotypic Surface: Pleiotropy Shapes the Co-Occurrence of Alcohol Use Disorder and Psychopathology	31
When Will There Be Good News?	31
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability	30
Innovative Directions to Advance Mental Health Disparities Research	30
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial	30
Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries	30
Differences in Social Determinants of Health Underlie Racial/Ethnic Disparities in Psychological Health and Well-Being: Study of 11,143 Older Adults	29
Psychiatric Diagnoses in Parents and Psychiatric, Behavioral, and Psychosocial Outcomes in Their Offspring: A Swedish Population-Based Register Study	29
Psychological Support for Psilocybin Treatment: Reply to Letters on Our Commentary	29
Evaluating the Evidence for Brain-Based Biotypes of Psychiatric Vulnerability in the Acute Aftermath of Trauma	29
Toward Precision Noninvasive Brain Stimulation	28
Setting the Record Straight on Long-Term Use, Dose Escalation, and Potential Misuse of Prescription Benzodiazepines	28
The Amygdala and Depression: A Sober Reconsideration	28
Correction	27
Auditory Steady-State Responses Probe GABA-Related Oscillatory Cortical Circuits and Their Relation to Neurodevelopmental Mental Disorders	27
2024 Articles of Import and Impact	27
Adolescent Suicidality and Depression, Premenstrual Dysphoric Disorder, and Safety Issues Related to Ketamine and Esketamine Treatment	26
Highlights From the Residents’ Journal: December 2024	26
Associations Between General and Specific Mental Health Conditions in Young Adulthood and Cardiometabolic Complications in Middle Adulthood: A 40-Year Longitudinal Familial Coaggregation Study of 672,	26
Understanding the Effects of Combined Lisdexamfetamine and Cognitive Behavior Therapy for Adults With Binge Eating Disorder	26
Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence	26
Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?	26
Technology and Mental Health: State of the Art for Assessment and Treatment	25
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future	25
Current and Future Approaches to Pediatric Anxiety Disorder Treatment	25
Converging Evidence for Frontopolar Cortex as a Target for Neuromodulation in Addiction Treatment	25
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial	25
Shared and Unique Changes in Brain Connectivity Among Depressed Patients After Remission With Pharmacotherapy Versus Psychotherapy	24
Progress and Challenges in GxE Research on Depression	24
Functional Connectivity Mapping for rTMS Target Selection in Depression	24
Antidepressants and Bipolar Disorder: The Plot Thickens	23
Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression	23
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them	23
Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donors’ Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia	23
Perinatal Mental Health: Advances and Opportunities	23
Guilt by Association: Inflammation and Shared Genetic Risk Between Stress-Related and Immune Disorders	23
Can Two 90-Minute Workshops Reduce Risk of Substance Use Disorder for Vulnerable Seventh Graders? Results and Scalability From the Co-Venture Trial	23
Vaccines as Immunotherapies for Substance Use Disorders	23
Late-Life Depression, Antidepressant Treatment, and Cognition: The Short Haul and the Long Haul	23
Cannabis Use and the Endocannabinoid System: A Clinical Perspective	23
Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon	23
Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?	22
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research	22
Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population	21
Psychotropic Drug–Related Weight Gain and Its Treatment	21
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction	21
Highlights From the Residents’ Journal: September 2023	20
Varenicline as a First-Line Treatment for Individuals With Current Major Depressive Disorder Who Smoke Cigarettes	20
The Evolving ADHD Phenotype in the Externalizing Context	20
Improved Response Inhibition Through Cognition-Guided EEG Neurofeedback in Men With Methamphetamine Use Disorder	20
Focusing on Substance Use Disorders, Opioids, and Craving	20
Putting Genetics to Work in the Psychiatric Clinic	19
Polygenic Risk Scores and Genetics in Psychiatry	19
Irremediable Psychiatric Suffering, a Potential Indication for Psilocybin Treatment	19
Intermittent Theta Burst Stimulation With Adjunctive D-Cycloserine for Obsessive-Compulsive Disorder: A Randomized Clinical Trial	19
Don’t Throw the Baby Out With the Bathwater: A Need for Nuanced Practice and Additional Research on Telehealth Management of ADHD	19
Neglect of Adverse Effects in Treatment Guidelines for Depression	19
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial	19
Neuropsychiatric Symptoms of Subacute and Chronic Long COVID	19
Effects of County-Level Opioid Dispensing Rates on Individual-Level Patterns of Prescription Opioid and Heroin Consumption: Evidence From National U.S. Data	18
The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders	18
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder	18
Clozapine’s High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies—How Do We Get There?	18
Reports to the Membership	18
Inner-Directed Therapy in MDMA-Assisted Psychotherapy	18

Pathogenic Variants and Ascertainment: Neuropsychiatric Disease Risk in a Health System Cohort	18
An Insula-Enriched Regulator of Retinoic Acid Marks a New Intersection in the Neural Circuitry of Mouse Social Behavior	18
Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia	18
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study	18
Highlights From the Residents’ Journal: June 2025	17
Affective Disorders, Pharmacogenomics, and Psychiatric Illness-Related Cardiometabolic Problems	17
Disclosure of Editors’ Financial Relationships	17
MORE Is Less Pain and Less Opioid Misuse: A Mindful Remedy	17
Beyond the Landmarks: Where to Next With Biomarkers of Autism?	17
Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark	16
Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?	16
Psychosis Risk With Prescription Amphetamine	16
Prospective Associations Between Structural Brain Development and Onset of Depressive Disorder During Adolescence and Emerging Adulthood	16
Intergenerational Effects of the Fast Track Intervention on Next-Generation Child Outcomes: A Preregistered Randomized Clinical Trial	16
Drug Overdose Prevention: An Exercise in Optimism	15
Seeking New Solutions Addressing Structural Racism, Childhood Trauma, Suicidal Behaviors Across Sexual Orientations, and Postpartum Depression	15
Association Between Polygenic Risk Scores and Outcome of ECT	15
Disclosure of Editors’ Financial Relationships	15
Treating Depression With Repetitive Transcranial Magnetic Stimulation: A Clinician’s Guide	15
The Intergenerational Impact of Structural Racism and Cumulative Trauma on Depression	15
Adolescent Substance Use and Suicidal Behavior, Internet Overuse, and Shared Genetics Between Problematic Alcohol Use and Other Psychiatric Comorbidities	15
MDMA and MDMA-Assisted Therapy	15
An Honest Reckoning With the Amygdala and Mental Illness	15